0R0H.L - Thermo Fisher Scientific Inc.
| Chiusura precedente | 518,29 |
| Aperto | 517,96 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 514,86 - 521,29 |
| Intervallo di 52 settimane | 476,29 - 608,54 |
| Volume | |
| Media Volume | 13.135 |
| Capitalizzazione | 2,099B |
| Beta (5 anni mensile) | 0,79 |
| Rapporto PE (ttm) | 0,27 |
| EPS (ttm) | 19,19 |
| Prossima data utili | 26 lug 2023 - 31 lug 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Data readout for TREK-AD Phase 2b study of eblasakimab on track for early July 2023Four abstracts on eblasakimab and farudodstat, including two late-breakers, to be presented at the 1st International Societies of Investigative Dermatology meeting May 10-13 in Tokyo$20 million private placement led by BVF Partners with the potential to receive up to an additional $80 million if all warrants are exercised in full Company maintains healthy operating position with US$57.5 million in cash and cash eq
- GlobeNewswire
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
TREK-AD Phase 2b study of eblasakimab fully enrolled, topline data readout expected early July 2023Phase 2 proof-of-concept trial of farudodstat in alopecia areata expected to commence in the second quarter of 2023 with topline data readout expected in the first quarter of 2024Expected cash runway extended through at least the second quarter of 2024 with recent $20 million in financing, with potential to receive up an additional $80 million SAN MATEO, Calif. and SINGAPORE, March 24, 2023 (GLOBE
- GlobeNewswire
ASLAN Pharmaceuticals and Thermo Fisher Scientific Announce Partnership to Manufacture High Concentration Formulation of Eblasakimab for Future Studies
Thermo Fisher Scientific to provide biologic manufacturing expertise and scale-up capacity to manage the clinical supply of eblasakimab for future Phase 3 studies A high concentration formulation of eblasakimab (200mg/ml) will be manufactured which could enable doses of up to 400mg eblasakimab to be delivered via a single subcutaneous injection SAN MATEO, Calif. and SINGAPORE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmace
GlobeNewswireMasterControl Honors Customers’ Achievements in Quality, Manufacturing, Analytics and Innovation at the Annual Masters of Excellence Gala.
SALT LAKE CITY, Oct. 26, 2022 (GLOBE NEWSWIRE) -- MasterControl, a provider of quality and manufacturing software solutions that enable life sciences and other regulated companies to deliver life-changing products to more people sooner, announced the 2022 Masters of Excellence Awards winners. The awards gala, which is part of the company’s Masters Summit 2022, recognizes customers that have excelled in innovation, digital transformation, and analytics. The Masters of Excellence Quality Champion
FX EmpireBest ETFs to Buy Now for July 2022
We’re midway through the year and are starting off the second half of what’s been a weird, rocky year so far.